NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE RESEARCH, INNOVATION AND NOVEL TECHNOLOGIES ADVISORY GROUP MEETING Tuesday 25 May 2021, from 10:30 – 14:30, via Microsoft Teams AGENDA

No.	Agenda Item	Action	Time
1.	Welcome and Apologies	GP	10:30 - 10:45
2.	Declarations of Interest in relation to the Agenda	All	10:45
3.	Minutes of the Research, Innovation and Novel Technologies Advisory Group Meeting held on 27 October 2020 – RINTAG(20)(M)2		10:45 – 11:00
3.1	Accuracy of the Minutes	All	
3.2	Action Points from the Research, Innovation and Novel Technologies Advisory Group Meeting held on 29 April See below		
AP6	Non-Transplant-Related Research Retrievals One of the questions asked at the last RINTAG Meeting was whether we would support research retrievals as a two-pronged affair, (i) to increase the competency and experience of the Teams, and (ii) to facilitate the use of organs for INOAR. Action: To set up a Steering Group and hold initial meeting to discuss Non-Transplant-Related Research Retrievals, and report back at the next RINTAG Meeting, or earlier by separate email.	DH/JC/IC/PF	
AP4.2	Organ utilisation for Research When islets are to be discarded if prep is insufficient for clinical use, labs can distribute organs to the network of studies which they support. RINTAG needs a list of projects that are supported in this way and how many preps are allocated to each study. Action: To take this issue to the Islet Consortium and Islet Steering Group, and report back. Action: To add this item to the Agenda for the next RINTAG Meeting, for discussion.	JC HC	
AP13.2	Shipment of Organox between Centres The process of shipment of Organox between Centres has previously been agreed at LAG however, given the time that has passed, and the issues caused by COVID, it may be worth putting this before LAG again. Action: To raise the issue of Organox shipments between Centres again with LAG, and report back.	cw	
Point 5	Study Re-Ranking Action: To amend the wording for the Edinburgh Study ranked 56, to show that this is an MRC funded study, so it is reviewed.	нт	
Point 7.2	Updates to the Research Organ Allocation Policy (POL263) for INOAR		

RINTAG(21)(A)1

14.	CTU – Update RINTAG(21)11	Alison Deary	14:20 14:20 -
13.	Update – Donor Optimisation Care Bundle Development	Gill Hardman	14:05 –
12.	COVID Antibody project	Michelle Willicombe	13:50 – 14:05
11.	Clinical Governance Update RINTAG(21)10	DM	13:35 – 13:50
10.	Shipment of SherpaPak hearts between centres	RV	13:20 – 13:35
9.	QUOD Report RINTAG(21)9	RP	13:15 – 13:30
8.	INOAR RINTAG(21)8	EL	13:00 – 13:15
	Lunch		12:30 - 13:00
7.3	Uncontrolled DCD Project – Cambridge RINTAG(21)7	Dom Summers	
7.2	NRP RINTAG(21)6	CW	
7.1	DCD Heart Activity RINTAG(21)5	LM	12:30
7.	Innovation		11:50 – 11:50 – 12:30
6.	New Studies and Resubmissions RINTAG(21)4(a) to 4(I)	нт	11:35 – 11:50
5.	Study Re-Ranking and Survey Feedback RINTAG(21)3 and 3(a)	НТ	11:20 - 11:35
4.2	Availability of Organs for Research RINTAG(21)2	LM	
4.1	Consent Research Consent/Authorisation Rates RINTAG(21)1	LM	
4.	Research Activity		11:00 - 11:20
Point 15	Cost Recovery of Organs/Tissues used in Research CD and PR presented various options to resolve this issue to the wider Business Developments Team, and the BDT have opted for a tiered approach Action: To volunteer to work with CD on the implementation of the tiered approach solution which has been agreed by BDT.	LA/CD/PF/AF/HB/ JC/DH/VG/RP/RB	
	but are still the subject of some discussion, so need revisiting. Action: To set up a Working Group to finalise Definitions contained in this paper, which needs to be resolved before January 2021.	LA/CD/PF/AF/HB/ JC/DH/VG/RP/RB	